Alglucosidase alfa - Sanofi Genzyme

Drug Profile

Alglucosidase alfa - Sanofi Genzyme

Alternative Names: Alglucosidase alpha; human acid alpha-glucosidase; Lumizyme; Myozyme; Pompase; recombinant human acid alpha-glucosidase; rhGAA

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Alpha-glucosidases; Peptides
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glycogen storage disease type II

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Apr 2017 Long term efficacy pooled data from a phase III and phase IV trial in Glycogen-storage-disease-type-II presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 01 Aug 2014 US FDA approves sBLA for alglucosidase alfa (Lumizyme®) for patients of any age or phenotype with Glycogen storage disease type II in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top